Elsevier

Neurobiology of Aging

Volume 33, Issue 2, February 2012, Pages 424.e11-424.e21
Neurobiology of Aging

Abstract of online article
Increased fMRI signal with age in familial Alzheimer's disease mutation carriers

https://doi.org/10.1016/j.neurobiolaging.2010.09.028Get rights and content

Abstract

Although many Alzheimer's disease (AD) patients have a family history of the disease, it is rarely inherited in a predictable way. Functional magnetic resonance imaging (fMRI) studies of nondemented adults carrying familial AD mutations provide an opportunity to prospectively identify brain differences associated with early AD-related changes. We compared fMRI activity of 18 nondemented autosomal dominant AD mutation carriers with fMRI activity in eight of their noncarrier relatives as they performed a novelty encoding task in which they viewed novel and repeated images. Because age of disease onset is relatively consistent within families, we also correlated fMRI activity with subjects' distance from the median age of diagnosis for their family. Mutation carriers did not show significantly different voxelwise fMRI activity from noncarriers as a group. However, as they approached their family age of disease diagnosis, only mutation carriers showed increased fMRI activity in the fusiform and middle temporal gyri. This suggests that during novelty encoding, increased fMRI activity in the temporal lobe may relate to incipient AD processes.

Introduction

Previous studies using functional magnetic resonance imaging (fMRI) to evaluate Alzheimer's disease (AD) risk have demonstrated that during memory tasks, nondemented older adults having increased genetic risk for AD showed differences in brain activity compared with those without such a risk (Bondi et al., 2005, Bookheimer et al., 2000, Filippini et al., 2009, Fleisher et al., 2005, Johnson et al., 2006, Lind et al., 2006, Xu et al., 2009). These studies have focused almost exclusively on the contributions to brain activity of allele ε4 of apolipoprotein E (APOE4), the genetic influence that has most consistently been shown to confer an increased risk of developing late onset AD across numerous studies (Bertram and Tanzi, 2008). However, although possession of an APOE4 allele increases the risk of developing AD at a younger age, the allele is neither necessary nor sufficient to cause the disease (Corder et al., 1993). Therefore, without later determining which subjects eventually develop AD, it is not possible to determine which APOE genotype-related differences are related to incipient AD in healthy adults and which are intrinsic to APOE4 without regard to AD processes.

Rare, early onset (typically before age 60), familial forms of AD exist, which are caused by mutations in one of three genes: presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor protein (APP). For carriers of these mutations, AD onset is governed by a fully-penetrant autosomal dominant inheritance (Bertram and Tanzi, 2008). Additionally, in such familial Alzheimer's disease (FAD), although age of onset may vary between families, it has been shown to be similar within families (Fox et al., 1997, Murrell et al., 2006). Therefore, for presymptomatic carriers of these mutations, it is possible to predict approximately when disease symptoms will begin. This certainty provides an excellent model for identifying the earliest AD-related changes prospectively. Differences between mutation carriers and noncarriers that are also seen in APOE4+ subjects performing a similar task may be evidence of AD-related processes that transcend gene polymorphism. Correlation of those variations with the number of years until expected age of disease symptoms in FAD mutation carriers would provide further support that the changes were associated with AD processes.

We compared the brain activity of nondemented adults carrying mutations in PSEN1 or APP with the brain activity of their family members who did not carry such a mutation as they performed a nonassociative novelty encoding task. Although mutations in PSEN1 and APP may have different effects on the brain, our goal was to identify functional brain patterns that generalized to prodromal AD without being specific to any one polymorphism. Also, the small number of subjects at risk for the individual mutation types makes meaningful comparisons more challenging. We therefore considered mutation carriers as a group regardless of mutation. The novelty encoding task we used engages regions of the hippocampus and surrounding cortex (Zeineh et al., 2000), and various similar tasks have been shown to be sensitive to differences in APOE genotype in cognitively intact adults (Bondi et al., 2005, Filippini et al., 2009, Johnson et al., 2006, Trivedi et al., 2006). Of these studies, two used tasks most similar to ours in that they involved the encoding of novel pictures (Bondi et al., 2005, Filippini et al., 2009) without the element of recognition decisions found in some other studies (Johnson et al., 2006, Trivedi et al., 2006). We hypothesized that our results would be most similar to those in a picture novelty encoding study of older (Bondi et al., 2005) rather than younger (Filippini et al., 2009) adults who, like our subjects, were presumably closer to AD onset in those destined to develop the disease. Specifically, we hypothesized that PSEN1 and APP mutation carriers in our study would show increased fMRI activity while viewing novel versus repeated images compared with mutation noncarriers. We further hypothesized that this increased activity would occur among regions that, in older APOE4+ subjects, had shown greater fMRI activity during the task in prior studies. These regions included parts of the temporal lobe (the fusiform and parahippocampal gyri and the hippocampus), the superior parietal lobule, and the medial and middle frontal gyri (Bondi et al., 2005). We anticipated that differences would be most striking in the temporal lobe, which is known to be affected early by Alzheimer's disease changes (Braak and Braak, 1995).

Section snippets

Subjects

Subjects were 26, cognitively intact or mildly cognitively impaired first-degree relatives of PSEN1 or APP mutation-carriers (age 19–46; mean 31.6 years) (Table 1). Cognitively intact subjects were those who did not meet the definition of AD or mild cognitive impairment (MCI) as defined below. Each underwent extensive clinical, cognitive, biochemical, and imaging evaluations. Subjects were cognitively intact except for five subjects who had MCI (Petersen, 2004). MCI was defined as those

Results

Using a normal approximation of a two-tailed Mann-Whitney test with a threshold of p < 0.05, mutation carriers and noncarriers were not significantly different in MMSE, CASI, or CDR score, sex, familial gene mutated, age, relative age, or possession of APOE4 (Table 1).

When all subjects were considered together, fMRI activity during novel pictures exceeded fMRI activity during previously viewed pictures in broad regions of the brain including areas important to episodic memory (such as the

Discussion

We found that when nondemented adults carrying fully-penetrant autosomal dominant Alzheimer's disease mutations approached the familial age of disease diagnosis, they showed greater fMRI activity in the fusiform and middle temporal gyri compared with mutation carriers who were further from the familial age of disease diagnosis. The fusiform gyrus is important in object processing (Tyler et al., 2004) and has been shown previously to be engaged during novelty encoding (Yamaguchi et al., 2004),

Disclosure statement

There were no actual or potential conflicts of interest that could inappropriately bias the authors work on this project.

Study procedures were approved by the Institutional Review Boards at UCLA and the National Institute of Neurology and Neurosurgery in Mexico City. All subjects signed written, informed consent.

Acknowledgements

This study was supported by PHS K08 AG-22228, California DHS #04-35522, UC MEXUS, and the Shirley and Jack Goldberg Trust. Further support for this study came from Alzheimer's Disease Research Center Grant P50 AG-16570 from the National Institute on Aging, General Clinical Research Centers Program M01-RR00865, and an Alzheimer's Disease Research Center of California grant, the Sidell Kagan Foundation, and the Easton Consortium for Alzheimer's Disease Drug Discovery and Biomarkers. MNB was

References (54)

  • J.B. Langbaum et al.

    Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI)

    Neuroimage

    (2009)
  • D.A. Loewenstein et al.

    Neuropsychological test performance and prediction of functional capacities among Spanish-speaking and English-speaking patients with dementia

    Arch. Clin. Neuropsychol.

    (1995)
  • Z. Qi et al.

    Impairment and compensation coexist in amnestic MCI default mode network

    Neuroimage

    (2010)
  • M.A. Trivedi et al.

    fMRI activation during episodic encoding and metacognitive appraisal across the lifespan: risk factors for Alzheimer's disease

    Neuropsychologia

    (2008)
  • C.E. Wierenga et al.

    Increased functional brain response during word retrieval in cognitively intact older adults at genetic risk for Alzheimer's disease

    Neuroimage

    (2010)
  • M.W. Woolrich et al.

    Temporal autocorrelation in univariate linear modeling of FMRI data

    Neuroimage

    (2001)
  • M.M. Zeineh et al.

    Application of cortical unfolding techniques to functional MRI of the human hippocampal region

    Neuroimage

    (2000)
  • L. Artiola-i-Fortuny et al.

    Manual de Normal y Procedimientos para la Bateria Neuropsicologia en Espanol

    (1999)
  • L. Bertram et al.

    Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses

    Nat. Rev. Neurosci

    (2008)
  • M.W. Bondi et al.

    fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease

    Neurology

    (2005)
  • S.Y. Bookheimer et al.

    Patterns of brain activation in people at risk for Alzheimer's disease

    N. Engl. J. Med

    (2000)
  • A. Caroli et al.

    Cerebral perfusion correlates of conversion to Alzheimer's disease in amnestic mild cognitive impairment

    J. Neurol

    (2007)
  • E.H. Corder et al.

    Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

    Science

    (1993)
  • B.C. Dickerson et al.

    Increased hippocampal activation in mild cognitive impairment compared with normal aging and AD

    Neurology

    (2005)
  • N. Filippini et al.

    Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele

    Proc. Natl. Acad. Sci. U. S. A.

    (2009)
  • A.S. Fleisher et al.

    Identification of Alzheimer disease risk by functional magnetic resonance imaging

    Arch. Neurol

    (2005)
  • N.C. Fox et al.

    Clinicopathological features of familial Alzheimer's disease associated with the M139V mutation in the presenilin 1 genePedigree but not mutation specific age at onset provides evidence for a further genetic factor

    Brain

    (1997)
  • Cited by (18)

    • Genetic and degenerative disorders primarily causing dementia

      2016, Handbook of Clinical Neurology
      Citation Excerpt :

      Despite the complexity of activation results, a bimodal pattern seems consistent. Medial temporal activation, increased in asymptomatic at-risk subjects (Quiroz et al., 2010; Putcha et al., 2011; Braskie et al., 2012; but see Ringman et al., 2011), tends to decrease as the AD process worsens and cognition deteriorates (Dickerson et al., 2004; O'Brien et al., 2010). Indeed, increased activation in mildly symptomatic, or even asymptomatic, individuals may predict their worsening (Dickerson et al., 2004; O'Brien et al., 2010).

    • Alzheimer's disease risk variant in CLU is associated with neural inefficiency in healthy individuals

      2015, Alzheimer's and Dementia
      Citation Excerpt :

      We suggest that this structural change may reflect a developmental vulnerability that reduces resilience to AD-related neuropathology, rather than early signs of AD-related neuropathology [24]. In sum, our findings support the hypothesis that increased genetic AD risk leads to functional changes in young healthy individuals that precede any clinical phenotypes [1–4,7,9–11,13,14,46,47]. The functional regions associated with CLU risk in the present study include areas that are implicated in the early stages of AD pathogenesis, where anatomical changes can precede the onset of clinical symptoms by several decades [48].

    • The capillary dysfunction hypothesis of Alzheimer's disease

      2013, Neurobiology of Aging
      Citation Excerpt :

      In asymptomatic APOE ε4 carriers, brain regions that are vulnerable to AD pathology have elevated resting CBF (Fleisher et al., 2009; Scarmeas et al., 2003; Thambisetty et al., 2010) and increased CBF responses during functional activation (Scarmeas et al., 2005), compared with control subjects. In addition, several functional magnetic resonance imaging studies reveal elevated blood oxygen level-dependent (BOLD) amplitudes in the mediotemporal cortex during memory encoding tasks in asymptomatic APOE ε4 carriers (Bookheimer et al., 2000; Braskie et al., 2010; Filippini et al., 2009; Fleisher et al., 2009; Trachtenberg et al., 2012). The biphasic nature of the CBF and BOLD changes during the course of the disease are illustrated in Fig. 1.

    View all citing articles on Scopus
    1

    Present address: SDSU/UCSD Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA.

    View full text